BioCentury | Mar 30, 2021
Deals

March 29 Quick Takes: SPAC carrying SomaLogic to NASDAQ; plus LianBio-Tarsus, Qihan, Biohaven, Tempest

...funds and accounts managed by Morgan Stanley’s Counterpoint Global, new strategic investor Illumina Inc. (NASDAQ:ILMN) and existing strategic investor...
BioCentury | Mar 3, 2021
Finance

European incubator Argobio targeting five new start-ups with €50M fund

European start-ups are getting another lift with the launch of Argobio, a French biotech incubator that aims to translate European science into at least one newco a year for the next five years. Founded by...
BioCentury | Jan 12, 2021
Finance

Seeking to fill gap in the clinic, LSP raises €50M toward dementia-focused fund

European investment firm LSP has launched a new dementia-focused fund to fill what it believes is a gap in support for development-stage companies evaluating treatments for neurodegenerative diseases. The firm has named Philip Scheltens, who...
BioCentury | Dec 11, 2020
Emerging Company Profile

Launching with $81M, Third Rock’s Faze is latest biotech seeking to unravel biomolecular condensates biology

Research into biomolecular condensates is gaining momentum with Third Rock launching the third company in the past month that aims to tackle the emerging space. On Thursday, the firm launched Faze Medicines Inc. to develop therapeutics targeting the...
BioCentury | Nov 14, 2020
Finance

Jeito adds dry powder to invest in European innovation

...French VC Jeito has added a second strategic investor...
BioCentury | Jul 23, 2020
Finance

Amid measured expansion, Longwood raises $170M for fifth fund

Although Longwood Fund’s latest vehicle is more than twice the size of its prior fund, the 10-year-old firm doesn’t expect to stray far from its strategy of launching start-ups with syndicated early rounds. The new...
BioCentury | May 21, 2020
Finance

HotSpot heads for clinic with $65M series B round to develop allosteric modulators

Allostery company HotSpot has added strategic and crossover investors to the mix for a $65 million series B round designed to take two small molecules into the clinic, but the company believes it will still...
BioCentury | Apr 28, 2020
Finance

Arch, Cormorant return to lead $200M megaround for Erasca

After adding over a half dozen pharma veterans to its R&D advisory board and advancing its cancer pipeline toward the clinic, Erasca has raised one of the year’s two largest venture rounds. Arch Venture Partners...
BioCentury | Apr 24, 2020
Emerging Company Profile

FoRx: A broader look at DNA damage repair

University of Geneva spinout FoRx debuted this week with €10 million in seed funding, a trio of strategic investors, and a new approach to synthetic lethality that could expand the cancer-killing mechanism to a broad...
BioCentury | Apr 4, 2020
Finance

Steady as venBio goes

A day after Arch and Flagship unveiled dueling billion dollar funds, venBio is staying the course with a more modest $394 million fund. What is new for the nine-year-old firm is a dramatic shift away...
Items per page:
1 - 10 of 118
BioCentury | Mar 30, 2021
Deals

March 29 Quick Takes: SPAC carrying SomaLogic to NASDAQ; plus LianBio-Tarsus, Qihan, Biohaven, Tempest

...funds and accounts managed by Morgan Stanley’s Counterpoint Global, new strategic investor Illumina Inc. (NASDAQ:ILMN) and existing strategic investor...
BioCentury | Mar 3, 2021
Finance

European incubator Argobio targeting five new start-ups with €50M fund

European start-ups are getting another lift with the launch of Argobio, a French biotech incubator that aims to translate European science into at least one newco a year for the next five years. Founded by...
BioCentury | Jan 12, 2021
Finance

Seeking to fill gap in the clinic, LSP raises €50M toward dementia-focused fund

European investment firm LSP has launched a new dementia-focused fund to fill what it believes is a gap in support for development-stage companies evaluating treatments for neurodegenerative diseases. The firm has named Philip Scheltens, who...
BioCentury | Dec 11, 2020
Emerging Company Profile

Launching with $81M, Third Rock’s Faze is latest biotech seeking to unravel biomolecular condensates biology

Research into biomolecular condensates is gaining momentum with Third Rock launching the third company in the past month that aims to tackle the emerging space. On Thursday, the firm launched Faze Medicines Inc. to develop therapeutics targeting the...
BioCentury | Nov 14, 2020
Finance

Jeito adds dry powder to invest in European innovation

...French VC Jeito has added a second strategic investor...
BioCentury | Jul 23, 2020
Finance

Amid measured expansion, Longwood raises $170M for fifth fund

Although Longwood Fund’s latest vehicle is more than twice the size of its prior fund, the 10-year-old firm doesn’t expect to stray far from its strategy of launching start-ups with syndicated early rounds. The new...
BioCentury | May 21, 2020
Finance

HotSpot heads for clinic with $65M series B round to develop allosteric modulators

Allostery company HotSpot has added strategic and crossover investors to the mix for a $65 million series B round designed to take two small molecules into the clinic, but the company believes it will still...
BioCentury | Apr 28, 2020
Finance

Arch, Cormorant return to lead $200M megaround for Erasca

After adding over a half dozen pharma veterans to its R&D advisory board and advancing its cancer pipeline toward the clinic, Erasca has raised one of the year’s two largest venture rounds. Arch Venture Partners...
BioCentury | Apr 24, 2020
Emerging Company Profile

FoRx: A broader look at DNA damage repair

University of Geneva spinout FoRx debuted this week with €10 million in seed funding, a trio of strategic investors, and a new approach to synthetic lethality that could expand the cancer-killing mechanism to a broad...
BioCentury | Apr 4, 2020
Finance

Steady as venBio goes

A day after Arch and Flagship unveiled dueling billion dollar funds, venBio is staying the course with a more modest $394 million fund. What is new for the nine-year-old firm is a dramatic shift away...
Items per page:
1 - 10 of 118